MET-097i: A Next-Generation Ultra-Long Acting GLP-1 Receptor Agonist

toegevoegd een audio Health

2025-11-11 09:26:26

Introduction to MET-097i and Its Potential MET-097i is emerging as a promising advancement in GLP-1 receptor agonists, developed by Metsera, a biotech company focused on innovative metabolic and cardiometabolic therapies. This fully biased, ultra-long acting GLP-1 receptor agonist is designed to provide sustained therapeutic benefits while improving tolerability. Built on the Metsera HALO...

0 Reacties 0 aandelen 55 Views 0 voorbeeld